Dette skyldtes, at pioglitazon mindskede den maternale hyperinsulinæmi og øgede insulinresistensen, som optræder under graviditet og derved reducerer tilgængeligheden af metaboliske substrater til fostervækst.
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.